CASR and neoplasm: Targeting this pathway by inhibiting CaSR signalling via treatment with the CaSR negative allosteric modulator NPS-2143, and mammary gland-specific deletion of the Casr gene, reduced tumour cell proliferation and PTHrP secretion (Kim et al. 2016).